Yahoo Finance Video
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names have been often cited as top picks in the pharmaceutical industry, are there hidden gems to look out for or do Eli Lilly and Novo Nordisk remain at the top of the class? Mizuho Healthcare Equity Strategist Jared Holz joins Morning Brief to give insight into the healthcare sector and what investors should keep in mind moving forward. "I think for me, Novo and Lilly are still going to be the top two. You know, as long as they are dominating in this kind of section of the market, it's really tough to not ride these a little bit longer, as far as other players in the GLP one market that might emerge that are of interest or intrigue to investors," Holz says. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino Follow Yahoo Finance's latest coverage on Eli Lilly and Novo Nordisk, weight-loss drugs, and the pharmaceutical industry as a whole: How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs Eli Lilly seeks to expand Zepbound use to treat sleep apnea Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market Why the GLP-1 impact on other industries 'will take years' Eli Lilly unveils new manufacturing plant for GLP-1 pens Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs Eli Lilly's new Alzheimer's treatment could 'lift' drug market Novo Nordisk stock rises on Wegovy approval in China
